Heart failure is the most common health concern for aging veterans. At the cellular and molecular level, heart failure is the result of cardiomyocyte contractile failure due to impairment of cardiac excitation-contraction (E-C) coupling process. E-C coupling is the central mechanism governing cardiomyocyte contraction. One critical structural component of E?C coupling is the myocyte transverse (T)-tubule system. T-tubules are orderly invaginations of surface membrane into the cell interior and are critical for rapid electric excitation and synchronous triggering of sarcoplasmic reticulum Ca2+ release, and therefore, coordinated contraction of each contractile unit throughout the entire myocyte. In failing myocytes from animal models and human patients, we and others have shown that the regularly arrayed T-tubule system undergoes disruptive remodeling, leading to aberrant intracellular Ca2+ release and compromised myocyte contractility. A long-term goal of my research program is to achieve a better understanding of the mechanisms underlying T-tubule damage in different types of heart disease, and to identify new strategies that can restore or repair T-tubule integrity and thereby improve or even rescue cardiac function. Towards identifying putative mechanisms for T-tubule repair, we have detected increased expression of Mitsugumin 53 (MG53, also known as TRIM72) in human failing hearts and animal models of chronic heart failure. MG53 is a novel muscle-specific protein involved in membrane vesicle trafficking and membrane repair following acute injury. Our pilot data showed that exogenous MG53 overexpression in short term protects against T-tubule damage, but chronic long-term overexpression of MG53 results in severe T-tubule disruption. These seemingly opposite data led to the hypothesis that MG53-mediated membrane repair is necessary in the short term to protect against T-tubule damage in response to cardiac stress, whereas chronic long-term upregulation of MG53 leads to myocyte T-tubule membrane damage and E- C coupling dysfunction instead of membrane repair. We will test this hypothesis in three aims: 1) Determine the role of MG53 upregulation in T-tubule integrity and heart failure progression in cardiomyopathy; 2) Define the mechanisms by which MG53 regulates T-tubule integrity in cardiomyocytes; and 3) Determine the molecular mechanism of MG53 upregulation in heart failure. Our study will define the role for long-term upregulation of the membrane repair protein, MG53, in damage of the T-tubule membrane structure in human and mouse models, which is a completely unstudied area. Understanding these molecular mechanisms will provide a new platform and guide us to design better MG53/T-tubule-targeted therapeutics for heart failure treatment by promoting repairs while avoiding the side effects.
Heart failure is the most common health concern for aging veterans. Over the last decade the number of resources used to treat heart failure within the VA healthcare system has grown steadily. New treatments that both improve patient outcomes and reduce the cost of care associated with heart failure will provide significant benefit to the VA healthcare system. Accomplishment of our studies will advance our understanding and provide new insights into the mechanisms of the novel membrane repair protein MG53 in heart failure pathophysiology and is expected to have an important positive impact for veterans by revealing new targets for heart failure therapeutics.
